Testing of P2Y-receptor antagonist effects can support clinical decision-making. However, most platelet function assays use only ADP as agonist which is not P2Y-receptor specific. For this reason P2Y-receptor specific assays have been developed by adding prostaglandin E1 (PGE1) to reduce ADP-induced platelet activation via the P2Y-receptor. The present study sought to evaluate a P2Y-receptor specific assay for determination of pharmacodynamic and clinical outcomes. This study enrolled 400 patients undergoing coronary stenting after loading with clopidogrel or prasugrel. ADP-induced platelet reactivity was assessed by whole blood aggregometry at multiple time points with a standard ADP assay (ADPtest) and a P2Y-receptor specific assay (ADPtest HS, both run on Multiplate Analyzer, Roche Diagnostics). Patients were clinically followed for 1 month and all events adjudicated by an independent committee. In total, 2084 pairs of test results of ADPtest and ADPtest HS were available showing a strong correlation between results of both assays (r = 0.96, p < 0.001). These findings prevailed in multiple prespecified subgroups (e.g., age; body mass index; diabetes). Calculated cutoffs for ADPtest HS and the established cutoffs of ADPtest showed a substantial agreement for prediction of ischemic and hemorrhagic events with a Cohen's κ of 0.66 and 0.66, respectively. The P2Y-receptor specific ADPtest HS assay appears similarly predictive for pharmacodynamic and clinical outcomes as compared to the established ADPtest assay indicating its applicability for clinical use. Further evaluation in large cohorts is needed to determine if P2Y-receptor specific testing offers any advantage for prediction of clinical outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/09537104.2016.1153620 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.
JACC Cardiovasc Interv
November 2024
Medizinische Klinik und Poliklinik I, University Hospital Munich, Ludwig-Maximilians University, Munich, Germany; Privatklinik Lauterbacher Mühle am Ostsee, Seeshaupt, Germany.
Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is associated with increased bleeding which may outweigh the benefits. This has set the foundations for customizing antiplatelet treatments to the individual patient.
View Article and Find Full Text PDFReassessing the role of aspirin in patients with coronary artery disease.
Expert Opin Pharmacother
December 2024
Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA.
Article Synopsis
- * Ongoing research is evaluating whether aspirin can be safely discontinued in favor of P2Y receptor inhibitor therapy, but there is still no consensus on the best timing for discontinuation.
- * New findings suggest that using P2Y inhibitors alone may pose a lower risk of bleeding, prompting a reevaluation of aspirin's role, while exploring innovative formulations and delivery methods like inhaled aspirin for improved patient care.
Ticagrelor and Statins: Dangerous Liaisons?
Cardiovasc Drugs Ther
December 2024
Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Viale Pieraccini 6, Florence, Italy.
Polypharmacy is often necessary in complex, chronic, comorbid and cardiovascular patients and is a known risk factor for potential drug-drug interaction (DDI) that can cause adverse reactions (toxicity or therapeutic failure). Anti-thrombotic drugs (largely low-dose aspirin and a platelet P2Y12 receptor inhibitor) and statins are among the most co-administered drugs in cardiovascular patients. Ticagrelor is a selective antagonist of the platelet P2Y12-receptor, highly effective in inhibiting platelet aggregation and bio-transformed by the CYP3A4 and substrate of transporters, such as the breast cancer resistance protein (BCRP).
View Article and Find Full Text PDFThe effect of gene polymorphism on ticagrelor metabolism: an study of 22 CYP3A4 variants in Chinese Han population.
PeerJ
September 2024
School of Pharmacy, Wenzhou Medical University, Wenzhou, China.
Article Synopsis
- Ticagrelor, an oral antiplatelet drug, selectively inhibits the P2Y12 receptor, but can cause side effects such as bleeding and dyspnea, which are linked to its plasma concentration.
- The study aimed to investigate how 22 different CYP3A4 gene variants, found in the Chinese Han population, affect the metabolism of ticagrelor.
- Results showed that most CYP3A4 variants had significant differences in how they cleared ticagrelor, with some having much higher or lower activity than the wild-type, indicating the need for personalized treatment approaches.
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor.
Int J Cardiol
December 2024
Department of Internal Medicine (Di.M.I.), University of Genoa, Genoa, Italy; Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, IRCCS Italian Cardiology Network, Genova, Italy. Electronic address:
Article Synopsis
- * Researchers reviewed data from 1,071 patients and found that factors like age over 75, acute coronary syndrome, and femoral access are significant predictors of bleeding risks classified as BARC 2-5 within 48 hours post-PCI.
- * They developed a new risk score, the "ICARUS score," which effectively predicts high bleeding risk and outperforms existing scoring systems in terms of accuracy and reliability.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!